Blue Flower

Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

The documentations contained in this archive section are provided for historical purposes only. The information contained in each documentation is accurate only as of the date each documentation was originally issued. NOXXON disavows any obligation to update the information contained in such documentations after the date of their issuance.

2018, May - ASCO Presentation
2018, May - Bio€quity Presentation
2017, October - Corporate Presentation

2017, July 11 - NOXXON Pharma NV Prospectus approved 10 July 2017 (English with summary of prospectus in French)

Overview and Characteristics of the Notes and Warrants of the financing agreement signed on May 01, 2017
2018, August 13 - Updated Summary Table of ODIRNANE & BSA
2017, May 02 - Characteristics of the Warrants
2017, May 02 - Characteristics of the Notes

2018, April 30 - 2017 Annual Report
2017, June 07 - 2016 Annual Report - statutory
2017, April 30 - 2016 Annual Report - non statutory

2016, December 07 - 2015 NOXXON Pharma N.V. IFRS

2017, Half-Year Financial Report as of 30 June 2017
2017, October 30 - Condensed consolidated interim financial statements as of 30 June 2017 
2016, October 31 - Condensed consolidated interim financial statements as of 30 June 2016

2016, September 28 - Information Document